» Articles » PMID: 34846993

Opioid Use During Pregnancy: An Analysis of Comment Data from the 2016 Pregnancy Risk Assessment Monitoring System Survey

Overview
Journal Subst Abus
Publisher Sage Publications
Date 2021 Nov 30
PMID 34846993
Authors
Affiliations
Soon will be listed here.
Abstract

ABTSTRACT Opioid misuse during pregnancy has been associated with adverse infant outcomes including preterm birth, stillbirth, and neonatal opioid withdrawal syndrome. The Pregnancy Risk Assessment Monitoring System (PRAMS) is an on-going state-based surveillance system of maternal behaviors, attitudes, and experiences prior to, during, and after pregnancy. : We analyzed qualitative comments related to opioid use during pregnancy collected in 2016 from an open-ended prompt at the end of the PRAMS survey in 35 states ( = 40,408). Key word searches were conducted on the open-ended responses ( = 9,549) to identify opioid-related content with an automated function using Microsoft Excel. All responses from the initial screening ( = 1,035) were manually reviewed, and 69 responses were confirmed to relate to the respondent's personal experience with opioid use during pregnancy. Content analysis was conducted by 3 independent coders; key themes were compiled, discussed, and finalized by the coding team. : Five key themes related to opioid use during pregnancy were identified: (1) gratitude for treatment, recovery, and healthy infants; (2) pregnancy as motivation to seek treatment; (3) difficulty finding prenatal care providers with training in substance use disorders; (4) concern about the effects of treatment on the infant; and (5) experiences of discrimination and stigma in the hospital around the time of delivery. : Women may be aware of the potential impact of opioid use during pregnancy on the health of their infants and motivated to seek treatment. Findings may help inform new and ongoing initiatives designed to improve care and reduce stigma for women needing or seeking treatment.

References
1.
Sokol R, Albanese C, Chaponis D, Early J, Maxted G, Morrill D . Why use group visits for opioid use disorder treatment in primary care? A patient-centered qualitative study. Subst Abus. 2017; 39(1):52-58. DOI: 10.1080/08897077.2017.1356792. View

2.
Kroelinger C, Rice M, Cox S, Hickner H, Weber M, Romero L . State Strategies to Address Opioid Use Disorder Among Pregnant and Postpartum Women and Infants Prenatally Exposed to Substances, Including Infants with Neonatal Abstinence Syndrome. MMWR Morb Mortal Wkly Rep. 2019; 68(36):777-783. PMC: 6753967. DOI: 10.15585/mmwr.mm6836a1. View

3.
Klaman S, Isaacs K, Leopold A, Perpich J, Hayashi S, Vender J . Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance. J Addict Med. 2017; 11(3):178-190. PMC: 5457836. DOI: 10.1097/ADM.0000000000000308. View

4.
Ko J, Tong V, Haight S, Terplan M, Stark L, Snead C . Obstetrician-gynecologists' practices and attitudes on substance use screening during pregnancy. J Perinatol. 2019; 40(3):422-432. PMC: 7047638. DOI: 10.1038/s41372-019-0542-3. View

5.
Wilson N, Kariisa M, Seth P, Smith 4th H, Davis N . Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020; 69(11):290-297. PMC: 7739981. DOI: 10.15585/mmwr.mm6911a4. View